Therapeutic Area

SGLT2 Inhibitor

Therapeutic area intelligence for SGLT2 Inhibitor with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Jiangsu Hansoh Pharma →

Assets

Dapagliflozin →

TRAVERE →

Recent signals(2)

RegulatoryJune 10, 2026

FDA Accepts Supplement for FILSPARI (SPARSENTAN) by TRAVERE

The FDA has accepted a supplemental application for FILSPARI (SPARSENTAN) from TRAVERE.

CompetitiveJune 6, 2026

FDA Submission for Dapagliflozin by Jiangsu Hansoh Pharma

Jiangsu Hansoh Pharma has submitted an original application (ANDA216119) for Dapagliflozin, currently under standard review.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.